Advertisement
Expression of concern
Open Access    |     10.1172/JCI199125
10.1172/JCI199125
				Find articles by
				Meakin, P.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
Find articles by Coull, B. in: PubMed | Google Scholar
Find articles by Tuharska, Z. in: PubMed | Google Scholar
Find articles by McCaffery, C. in: PubMed | Google Scholar
				Find articles by
				Akoumianakis, I.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
				Find articles by
				Antoniades, C.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
Find articles by Brown, J. in: PubMed | Google Scholar
Find articles by Griffin, K. in: PubMed | Google Scholar
Find articles by Platt, F. in: PubMed | Google Scholar
				Find articles by
				Ozber, C.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
				Find articles by
				Yuldasheva, N.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
Find articles by Makava, N. in: PubMed | Google Scholar
Find articles by Skromna, A. in: PubMed | Google Scholar
Find articles by Prescott, A. in: PubMed | Google Scholar
				Find articles by
				McNeilly, A.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
Find articles by Siddiqui, M. in: PubMed | Google Scholar
Find articles by Palmer, C. in: PubMed | Google Scholar
				Find articles by
				Khan, F.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
				Find articles by
				Ashford, M.
				in:
				PubMed
				 |
				Google Scholar
				 
					|
					 
					
			
Published September 2, 2025 - More info
 
Diabetes, obesity, and Alzheimer’s disease (AD) are associated with vascular complications and impaired nitric oxide (NO) production. Furthermore, increased β-site amyloid precursor protein–cleaving (APP-cleaving) enzyme 1 (BACE1), APP, and β-amyloid (Aβ) are linked with vascular disease development and increased BACE1 and Aβ accompany hyperglycemia and hyperlipidemia. However, the causal relationship between obesity and diabetes, increased Aβ, and vascular dysfunction is unclear. We report that diet-induced obesity (DIO) in mice increased plasma and vascular Aβ42 that correlated with decreased NO bioavailability, endothelial dysfunction, and increased blood pressure. Genetic or pharmacological reduction of BACE1 activity and Aβ42 prevented and reversed, respectively, these outcomes. In contrast, expression of human mutant APP in mice or Aβ42 infusion into control diet–fed mice to mimic obese levels impaired NO production, vascular relaxation, and raised blood pressure. In humans, increased plasma Aβ42 correlated with diabetes and endothelial dysfunction. Mechanistically, higher Aβ42 reduced endothelial NO synthase (eNOS), cyclic GMP (cGMP), and protein kinase G (PKG) activity independently of diet, whereas endothelin-1 was increased by diet and Aβ42. Lowering Aβ42 reversed the DIO deficit in the eNOS/cGMP/PKG pathway and decreased endothelin-1. Our findings suggest that BACE1 inhibitors may have therapeutic value in the treatment of vascular disease associated with diabetes.
Paul J. Meakin, Bethany M. Coull, Zofia Tuharska, Christopher McCaffery, Ioannis Akoumianakis, Charalambos Antoniades, Jane Brown, Kathryn J. Griffin, Fiona Platt, Claire H. Ozber, Nadira Y. Yuldasheva, Natallia Makava, Anna Skromna, Alan Prescott, Alison D. McNeilly, Moneeza Siddiqui, Colin N.A. Palmer, Faisel Khan, Michael L.J. Ashford
Original citation: J Clin Invest. 2020;130(8):4104–4117. https://doi.org/10.1172/JCI122237
Citation for this Expression of Concern: J Clin Invest. 2025;135(17):e199125. https://doi.org/10.1172/JCI199125
The Editors recently became aware of blot anomalies in Figures 6A and 7A. The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.
See the related article at Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
 
 
